Commonly used PIs such as Bortezomib, Ixazomib, and Carfilzomib; IMiDs including Lenalidomide, Iberdomide, and Pomalidomide; and monoclonal antibodies such as anti-CD38 mAbs like Daratumumab, as well as anti-SLAMF7 mAbs like Elotuzumab, are often combined with chemotherapeutic drugs such as fludarabine and cyclophosphamide in MM CAR T-cell therapies [12, 194] (Table 4). This evidence concerns the gene CD38 and Miyoshi myopathy.